View Item 

Show simple item record

Is it better to treat chronic hepatitis B as early as possible?—Con

dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T20:23:55Z
dc.date.available2010-06-01T20:23:55Z
dc.date.issued2004-12en_US
dc.identifier.citationLOK, ANNA SF (2004). "Is it better to treat chronic hepatitis B as early as possible?—Con." Journal of Gastroenterology and Hepatology 19(s7): S120-S123. <http://hdl.handle.net/2027.42/73513>en_US
dc.identifier.issn0815-9319en_US
dc.identifier.issn1440-1746en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73513
dc.description.abstractIdeally, treatment of chronic hepatitis B in its early stage prior to irreversible liver damage should be most effective in preventing adverse clinical outcome. However, currently available treatments have low efficacy in achieving sustained response among patients in the early phase of chronic hepatitis B infection when the immune response to hepatitis B virus is weak. This review will provide evidence why a ‘wait and monitor’ approach is appropriate for chronic hepatitis B patients who are in the immune tolerant phase.en_US
dc.format.extent55027 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ptyen_US
dc.rights2004 Blackwell Publishing Asia Pty Ltden_US
dc.subject.otherAdefovir Dipivoxilen_US
dc.subject.otherHepatitis B E Antigenen_US
dc.subject.otherImmune Toleranceen_US
dc.subject.otherInterferonen_US
dc.subject.otherLamivudineen_US
dc.titleIs it better to treat chronic hepatitis B as early as possible?—Conen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* University of Michigan, Ann Arbor, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73513/1/j.1440-1746.2004.03660.x.pdf
dc.identifier.doi10.1111/j.1440-1746.2004.03660.xen_US
dc.identifier.sourceJournal of Gastroenterology and Hepatologyen_US
dc.identifier.citedreferenceLok AS, McMahon BJ. Chronic hepatitis B—Practice Guidelines Committee, AASLD. Hepatology 2001; 34: 1225 – 41.en_US
dc.identifier.citedreferenceLok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857 – 61.en_US
dc.identifier.citedreferencede Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. 2003; 39 ( Suppl. 1 ): S3 – 25.en_US
dc.identifier.citedreferenceLiaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003; 18: 239 – 45.en_US
dc.identifier.citedreferenceMilich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38: 1075 – 86.en_US
dc.identifier.citedreferenceHsu HY, Chang MH, Hsieh KH et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 770 – 6.en_US
dc.identifier.citedreferenceTsai SL, Chen PJ, Lai MY et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J. Clin. Invest. 1992; 89: 87 – 96.en_US
dc.identifier.citedreferenceLok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001; 120: 1828 – 53.en_US
dc.identifier.citedreferenceCraxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J. Hepatol. 2003; 39: S99 – 105.en_US
dc.identifier.citedreferenceLok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J. Viral Hepat. 1998; 5: 171 – 8.en_US
dc.identifier.citedreferencePerrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. [see comments]. N. Engl. J. Med. 1990; 323: 295 – 301.en_US
dc.identifier.citedreferenceLai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2: 877 – 80.en_US
dc.identifier.citedreferenceLai CL, Lin HJ, Lau JN et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q. J. Med. 1991; 78: 155 – 63.en_US
dc.identifier.citedreferenceLok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298 – 302.en_US
dc.identifier.citedreferenceLok AS, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091 – 7.en_US
dc.identifier.citedreferenceLiaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J. Hepatol. 1994; 20: 175 – 80.en_US
dc.identifier.citedreferenceCooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10: 298 – 305.en_US
dc.identifier.citedreferenceDienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256 – 63.en_US
dc.identifier.citedreferenceLai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61 – 8.en_US
dc.identifier.citedreferenceSchalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562 – 8.en_US
dc.identifier.citedreferenceJonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 2002; 346: 1706 – 13.en_US
dc.identifier.citedreferencePerrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186 – 94.en_US
dc.identifier.citedreferenceLiaw YF. Results of lamivudine trials in Asia. J. Hepatol. 2003; 39 ( Suppl. 1 ): S111 – 15.en_US
dc.identifier.citedreferenceMarcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 808 – 16.en_US
dc.identifier.citedreferenceLim SG, Marcellin P, Tassopoulos NC et al. Lack of ethnic differences in response to adefovir dipivoxil therapy in HBeAg+ and HBeAg- patients with chronic hepatitis B. Hepatology 2003; 34: 714A – 715A.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1440-1746.2004.03660.x.pdf
Size:
53.73KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.